Open AccessRelvar Ellipta® - new molecule in a new delivery system - new horizons in the treatment of bronchial asthma
Author(s) -
Evgeniya V. Nazarova,
Evgeniya V. Nazarova,
Elena A. Latysheva,
Латышева Елена Александровна
Publication year - 2015
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja457
Subject(s) - asthma , medicine , inhalation , drug delivery , intensive care medicine , disease control , drug , pharmacology , anesthesia , nanotechnology , materials science , virology
Bronchial asthma is a serious socio-economic problem despite of the availability of highly effective therapy for control of symptoms. The gold standard of asthma therapy is high effective and safe combination of ICS+LABA. However, even use of these drugs leave more than half of patients around the world without full control over the symptoms of the disease. This leads for necessity of the search of new therapies - molecules as new drugs and new means for delivery, allowing to minimize technical errors during the inhalation manoeuvre, improving patient treatment adherence. This drug is Relvar Ellipta® containing a combination of new molecules of ICS and LABA in a new, improved delivery system for use 1 time per day.